Tag: Nasdaq:RVPH
Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering
CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical...
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results...
Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective DisorderMet primary endpoint of reduction in Positive...
Reviva Pharmaceuticals Holdings, Inc. to Present at the Maxim Group Inaugural 2021...
CUPERTINO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the...